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Abstract: BACKGROUND Heterocyclic amines (HCA) are potent carcinogenic substances formed in
meat. Because of their mutagenic activity, they may increase the risk of colorectal adenomas, which
are the precursors of colorectal cancer, one of the most prevalent cancers worldwide. The aim of this
meta-analysis was to synthesize the knowledge about the intake of HCAs and its associations with CRA.
METHODS We conducted a systematic search in PubMed and EMBASE. We used odds ratios (OR); or
relative risks, RR) from every reported intake and compared the highest versus lowest level of dietary
HCAs. In addition, we assessed a dose-response relationship. RESULTS Twelve studies on HCA intake
and risk of CRA were included in our analysis. We observed a statistically significant association when
comparing top versus bottom intake category of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine [PhIP;
OR = 1.20; 95% confidence interval (CI) = 1.12-1.29], 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline
(MeIQx; OR = 1.20; 95% CI = 1.08-1.34), 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx;
OR = 1.16; 95% CI = 1.05-1.27), benzo(a)pyrene (BaP; OR = 1.15; 95% CI = 1.04-1.27), and mutagenic-
ity index (OR = 1.22; 95% CI = 1.06-1.41). Furthermore, we observed a significant dose-response effect
for PhIP, MeIQx, and mutagenicity index. CONCLUSIONS This meta-analysis suggests that there is a
positive association of HCAs, BaP, mutagenicity index with risk of CRA. In addition, our dose-response
analyses showed an increased risk of CRA for PhIP, MeIQx, and mutagenicity index. IMPACT This
study provides evidence for a positive association between the dietary intake of meat mutagens and CRA
risk.
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Background: Heterocyclic amines (HCAs) are potent carcinogenic substances formed in meat. 
Due to their mutagenic activity, they may increase the risk of colorectal adenomas (CRA), 
which are precursors of colorectal cancer (CRC), one of the most prevalent cancers worldwide. 
The aim of this meta-analysis was to synthesize the knowledge about the intake of HCAs and 
its associations with CRA. 
Methods: We conducted a systematic search in PubMed and EMBASE. We used odds ratio 
(OR) (or relative risks, RR) from every reported intake and compared the highest versus lowest 
level of dietary HCAs. In addition, we assessed a dose-response relationship. 
Results: Twelve studies on HCA intake and risk of CRA were included in our analysis. We 
observed a significant association when comparing top versus bottom intake category of 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (OR= 1.20, 95% CI=1.12 to 1.29), 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) (OR=1.20; 95% CI=1.08 to 1.34), 2- 
amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx) (OR=1.16; 95% CI=1.05 to 1.27), 
benzo(a)pyrene (BaP) (OR=1.15; 95% CI=1.04 to 1.27) and mutagenicity index (OR=1.22;95% 
CI=1.06 to 1.41). Furthermore, we observed a significant dose-response effect for PhIP, MeIQx 
and mutagenicity index. 
Conclusion: This meta-analysis suggests that there is a positive association of HCAs, BaP, 
mutagenicity index with risk of CRA. Additionally, our dose-response analyses showed an 
increased risk for CRA in the case of PhIP, MeIQx and mutagenicity index. 
Impact: This study provides evidence for a positive association between the dietary intake of 
meat mutagens and CRA risk. 




In 2017, about 135,430 new cases of colorectal cancer (CRC) will be diagnosed in the United 
States and 50,260 persons will die from the disease [1]. In 2012, the International Agency for 
Research on Cancer (IARC) estimated that CRC was the third most common cancer worldwide 
in men and the second in women [2]. About 95% of CRCs emanate from benign, neoplastic 
adenomatous polyps (adenomas) [3], which are found in up to 40% of a population by the age 
of 60 [4]. More than 50% of CRCs occur in developed countries, being Oceania and Europe the 
ones with the highest incidence [5]. Common risk factors are age, race, family history of CRC 
and lifestyle, including sedentarism, smoking and Western dietary patterns [1, 6]. Meat 
consumption, especially red and processed meat, has been identified as an important dietary 
risk factor for CRC and colorectal adenomas (CRA) [7, 8]. Based on the results of several 
epidemiological studies, in October 2015, the IARC evaluated the association between red, 
processed meat and cancer and classified the consumption of red meat as probably 
carcinogenic to humans (Group 2A) with limited evidence and the consumption of processed 
meat as carcinogenic to humans (Group 1) with sufficient evidence [9]. After the decision of 
the IARC, more epidemiological studies and reviews have addressed this issue [8, 10]. Recently, 
Domingo et al. have reviewed the latest evidence, supporting the classification of red and 
processed meat as carcinogenic [11]. 
 
Several mechanisms have been suggested to explain the association between red and 
processed meat with CRC. Possible factors that may increase the carcinogenic process are 
cooking products found in meat such as heterocyclic amines (HCAs) and polycyclic aromatic 
hydrocarbons (PAH) [12]. Other compounds are nitrates and nitrites, which are characteristic 
of processed meat and that have been classified as a “probable human carcinogens (Group 
2A)” by the IARC [13] and heme iron, which is abundant in red meat.  
HCAs arise during the thermal processing of meat, fish and poultry at temperatures over 150 
degrees Celsius. Their formation depends on the type of meat and cooking method, and their 
amount increases with the duration and temperature of cooking [14]. Although more than 20 
HCAs have been identified [14], the three most abundant carcinogenic HCAs formed in meats 
are 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP), 2-amino-3,8-
dimethylimidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-3,4,8-trimethylimidazo[4,5-
f]quinoxaline (DiMeIQx) [15]. They are considered as potent carcinogenic substances, 
therefore, in 1993 PhIP, MeIQ and MeIQx were classified as “possible human carcinogens” 
(Group 2B) by the IARC [16]. Similarly, one of the PAHs, BaP, was also part of the list of 
carcinogens provided by the IARC. BaP was classified as “carcinogenic to humans” (Group 1) in 
2012 [17]. 
The purpose of this systematic review was to investigate the association of HCA and BaP intake 
with CRA risk. Additionally, we aimed to examine whether the association between these 
compounds and colorectal adenoma risk differed by adenoma site and sex. 
 
Materials and Methods 
Data sources and search strategy 
To identify eligible studies on the association of HCAs with CRA, a systematic literature search 
was conducted by two independent authors (VM, PC). Any disagreement was resolved after 
discussion with a third reviewer (SR). We searched in PubMed and EMBASE through March 
2017 with no limitations on year or language of publication. The following search terms were 
used: (“colorectal adenoma” OR “colorectal polyps”) AND (“heterocyclic amines” OR “PhIP” OR 
“MelQx” OR “DiMelQx” OR “polycyclic aromatic hydrocarbons” OR “meat”). Additionally, the 
reference lists of already identified articles were examined for other eligible studies based on 
the above-mentioned key words. Relevant studies were imported to EndNote (X7) to search 
for duplicates.  
We carried out this systematic review and meta-analysis according to the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) statement [18]. 
 
Study selection 
Studies were included in the systematic review if they 1) were cohort, case-control or cross-
sectional studies in humans; 2) investigated the association between HCAs and B(a)P intake 
and colorectal adenoma risk, 3) reported relative risk estimates (odds ratio [OR] or risk ratios 
[RR]) with 95% confidence intervals (CI) and if 4) the quantity of each single compound was 
stated. 
We selected the most recent publications that included the largest number of cases, excluding 
overlapping studies. We further excluded studies if they focused on adenoma recurrence or 
only examined genetics. 
Data extraction 
We reviewed the eligible studies and carried out the extraction of data. The following 
information were abstracted: first author’s last name, year of publication, country, study 
design, study size, number of cases and controls, sex, age, year diet was assessed, diet-
assessment method, follow-up time, HCAs, BaP, or total mutagenicity index, adenoma 
outcome, statistical adjustments for confounders, mutagen doses comparisons, and the OR/RR 
estimates with 95% CI for the highest versus lowest level of intake for each mutagen. 
Multivariable adjusted analyses were extracted in preference over crude measures.  
Quality assessment 
To assess the methodological quality of the studies, we used the Newcastle-Ottawa Quality 
Assessment Scale for cohort and case-control studies [19]. Each study was awarded a 
maximum of 9 points based on selection of controls, comparability and exposure in case of 
case-control studies, and outcome, in the case of cohort studies. The complete assessment is 
presented in supplementary tables 1 (cohort studies) and 2 (case-control studies). 
 
Statistical analysis 
We conducted meta-analyses utilizing OR (or RR) from every reported intake and we 
compared the highest versus lowest level of dietary mutagens. Primary meta-analyses models 
evaluate colorectal adenoma and the mutagen exposures. Forest plots were generated for the 
primary meta-analyses stratified by study type (i.e., cohort vs. case-control and cross-sectional 
studies). Further meta-analyses were performed stratified by adenoma site (colon and rectum) 
and sex to examine potential associations.  
We assessed dose-response relationships between HCAs and colorectal adenoma following the 
method of Greenland and Longnecker [20]. The method requires the number of cases and 
controls per exposure level (therefore, we could not include all studies; we excluded 3 studies 
[24 ,25 ,26]), the ORs with CI and the mean or median for each category. In a sensitivity 
analysis, we also excluded the study by Gunter et al. [27] because the maximum values in the 
top category were several times higher than the top intake in all other studies. We used cubic 
splines with the knots for quantiles 0.25, 0.5 and 0.75 to assess the association between the 
mutagen exposure and CRA. 
To evaluate heterogeneity of included studies, Cochran’s Q test and I2statistic were used. 
Publication bias was assessed with Egger’s test by creating funnel plots [21]. All analyses were 
conducted using the statistical program STATA software version 13.1 (College Station, Texas) 
and R version 3.3.2. 
 
Results 
Figure 1 shows our search results: Until March 23, 2017 334 publications from PubMed and 
139 from EMBASE were found. After screening, we included 12 publications (3 cohort [22-24], 
8 case-control [25-32] and 1 cross-sectional [33] studies; in the following, study [33] will also 
be considered a case-control study) that examined the association of dietary mutagen 
exposures (PhIP, MelQx, DiMelQx, total HCAs, BaP and mutagenicity index) with CRA in the 
systematic literature search. We excluded 6 studies because they overlapped with other 
publications [34, 35, 36, 37, 38, 39] or only explored adenoma recurrence [40]. 
Among eligible articles, 9 studies examined men and women [23-28, 30, 31, 33], 1 study that 
examined men and women only separately [32], 1 male cohort [22], and 1 female case-control 
study [29]. Most of the studies were from the United States [22, 24-31], one was from Canada 
[33], another one from Japan [32], and one was conducted in Europe [23]. A total of 76,657 
participants including 9,995 colorectal adenoma cases were evaluated in this meta-analysis. 
Table 1 shows descriptive study characteristics of the studies; supplementary table 3 provides 
details on HCA assessment. 
PhIP 
Eleven studies on PhIP intake and CRA were included in the meta-analysis [22-25, 27-33]. 
Overall, dietary PhIP intake was related to increased risk of CRA (OR= 1.20, 95% CI= 1.12 to 
1.29 comparing top versus bottom intake category). No significant heterogeneity between 
studies was observed; Figure 2A shows that results were similar in case-control and cohort 
studies. Figure 3A reveals a positive the dose-response association between PhIP intake and 
CRA. For 40 ng /day, the OR was 1.14 (95% CI=1.02 to 1.29) and the p value was 0.0160. 
Supplementary figure 1 shows that excluding Gunter et al. [27] from the dose-response 
analysis changed the dose-response curve, but not the interpretation of our results (for 40 
ng/day: OR = 1.16, 95% CI=1.02 to 1.32; p value 0.0016). We performed sub-analyses by sex 
and site of adenoma (colon, rectum) [24, 27] and observed a significant association for colon 
adenoma, but not for rectal adenoma; results by sex were not statistically significant (Table 2). 
Figure 4A shows no indication of publication bias was observed from the funnel plot.  
MeIQx 
Eleven studies evaluated the association between MeIQx intake and CRA [22-25, 27-33] and 
were included in this meta-analysis. The meta-analysis resulted in a statistically significant 
association (OR=1.20, 95% CI=1.06 to 1.34, top versus bottom category) with no evidence of 
heterogeneity between studies as shown in Figure 2B. However, results of case-control studies 
were stronger than those of cohort studies. Table 2 revealed a statistically significant 
association between MeIQx intake and risk of adenomas in women. Figure 3B indicated a 
positive dose-response relationship between MeIQx and CRA. For 50 ng/day, the OR was 1.25 
(95% CI= 1.09 to 1.43) with a p value of 0.002 (excluding [27]: OR 1.28 [95% CI= 1.10 to 1.48]; 
 p-value = 0.0016; supplementary figure 1). Figure 4B gives no indication of publication bias. 
DiMeIQx 
Ten studies provided results for DiMeIQx intake and CRA [22-25, 27-32] and were included in 
the meta-analysis. We found a significant association between DiMeIQx intake and CRA 
(OR=1.16, 95% CI=1.05 to 1.28). Figure 2C does not indicate any heterogeneity between 
studies, but the association was stronger in case-control than in cohort studies. Table 2 shows 
no indication of an association between DiMeIQx and rectal adenoma; associations for colon 
adenomas and by sex were positive, but not statistically significant. In Figure 3C, no evidence 
of a dose-response relationship was observed for incremental intake levels of DiMeIQx. Figure 
4C does not provide any evidence of publication bias. 
BaP 
Six studies described the association of BaP intake and CRA [24, 26-29, 31] and were included 
in the meta-analysis. Figure 2D shows a positive association between BaP intake and CRA 
(OR=1.15, 95% CI=1.04 to 1.27, top versus bottom category). Only one cohort study reported 
on the association between BaP and CRA. Table 2 provides no evidence of heterogeneity 
between studies. Figure 3D shows no statistically significant relationship in the dose-response 
analysis. Figure 4D shows the funnel plot for BaP intake and CRA indicating no publication bias. 
Mutagenicity index 
Seven studies were identified that included data on meat-derived mutagenicity index and CRA 
[22, 24, 25, 27, 29, 31, 32]. Figure 2E shows the meta-analysis of studies between mutagenicity 
index and CRA with a positive association (OR=1.22 95% CI=1.06 to 1.42, top versus bottom 
category) and no statistically significant study heterogeneity (p=0.076). Only two cohort 
studies examined the association between mutagenicity index and CRA and their summary 
result was weaker than the association observed in case-control studies. No statistically 
significant associations were observed in the sub-analyses by adenoma site or sex (Table 2). 
Figure 3E shows a positive dose-response association between mutagenicity index and CRA. 
For 7000 revertants/day the OR was 1.26 (95% CI= 1.02 to 1.55) with a p value of 0.0003. 
Figure 4E shows the funnel plot for mutagenicity index with an indication of publication bias. 
 
Discussion 
The relationship between dietary HCAs, BaP, mutagenicity index and CRA has been a topic of 
debate for several years. In this meta-analysis, we examined the association of HCAs, BaP and 
mutagenicity index with CRA risk. When comparing the highest versus the lowest intake of 
PhIP, MeIQx, DiMeIQx, BaP and mutagenicity index, we found a statistically significant positive 
association with CRA for all exposures. In addition, we observed a significant dose-response 
effect in the case of PhIP, MeIQx and mutagenicity index. Only few cohort studies examined 
these associations and, besides PhIP, the results were weaker than in case-control studies. 
CRA is a precursor of CRC and its evolution to carcinoma occurs through the chromosomal or 
the microsatellite instability pathway. Genes affected by mutations can lead to most cancers 
[41], including CRC. The mutagenicity of HCAs and BaP has been demonstrated in animal 
studies [42]. One of the potential mechanisms that could explain this is the formation of DNA 
adducts [43(3)], which increases with the intake of dietary HCAs and BaP [44(4)]. Despite the 
knowledge of these mechanisms, the association between HCA and BaP intake and risk of CRC 
is less consistent than the association with CRA (see [45]). Also, although there is limited and 
inconsistent evidence, epidemiological studies have also reported an association between 
HCAs and breast [46, 47, 48], bladder [49] and prostate cancer [50, 51]. In fact, in order to 
damage DNA, these carcinogenic compounds need to be bioactivated by cytochrome P450 1A2 
and then by N-acetyltransferase-2. It has been observed that the population is not equally 
affected by the activity of these enzymes [37], and several studies [32, 33, 35-39] have 
investigated the role of genetics, HCAs and CRA risk. For instance, Voutsinas et al. observed an 
increased risk of CRA when the intake of HCAs was combined with a rapid NAT2 phenotype 
[37]. However, the association between NAT2 acetylation genotype and CRA was not 
supported by the investigation of Budhathoki et al. [32]. Additionally, Barbir et al. [38] found 
that HCA intake was positively associated with CRA risk independently of the phenotypes 
involved in the metabolism of HCA. 
It is well known that diet plays an important role in the process of colorectal carcinogenesis 
because the colon is exposed to several carcinogens, such as HCAs or BaP, resulting in a 
malignant transformation of the colonocytes [52]. Besides carcinogenic compounds found in 
meat, there are some other foods with anticarcinogenic properties that may be protective. For 
instance, Platt et al. evaluated the role of fruits and vegetables against the genotoxicity of 
HCAs, reporting positive effects [53]. Furthermore, Rohrmann et al. examined the intake of 
flavonoids, which are mainly found in fruits and vegetables, and observed a positive 
association of PhIP intake with adenoma risk in participants with a low flavonol intake [23]. In 
addition, Puangsombat et al. investigated the inhibitory activity of Asian spices and their 
results suggest that the addition of these spices can be relevant to decrease the levels of HCAs 
in beef [54]. Another factor that can influence the carcinogenicity of HCAs is the gut 
microbiota. Recently, experimental studies have shown how microbes can reduce the toxicity 
of HCAs in the gut [55]. 
Due to the low number of data available, we could only stratify the analysis by sex and 
adenoma site, without the possibility to analyze data from the different countries. The results 
of the sub-analysis were, with two exceptions, not statistically significant. However, it should 
be taken into account that the number of studies for site and sex were limited. 
 
Strengths and limitations 
Previously, a meta-analysis by Chiavarini et al. [56] examined the association between HCA 
intake and risk of CRA and CRC. However, they did not fully exclude overlapping publications 
(for example, Rohrmann et al. [23] and Barbir et al. [38] were both included although they 
analysed largely overlapping data; for details see Supplementary Table 4). Nevertheless, our 
results and those by Chiavarini are very similar although we included fewer studies.  
There are some challenges to evaluate exposures such as HCAs or BaP in epidemiological 
studies. First, it is well known that dietary questionnaires in general are a source of 
information bias. Second, the intake of HCAs is difficult to assess since their formation in meat 
changes according to the type of meat, cooking method, duration and temperature. Most 
studies used the Computarized Heterocyclic Amines Resource for Research in Epidemiology of 
Disease (CHARRED) to generate the intake estimates of HCAs. Biomarkers reflect exposure in 
the human body, which are considered more accurate measures than self-reported dietary 
questionnaires. Budhathoki et al. compared the intake of HCAs estimated from an FFQ against 
HCA levels measured in human hair [31]. In their validation study, Spearman rank correlation 
coefficients between HCA from the FFQ and in hair ranged between 0.32 and 0.55 [57]. 
We did not generally observe large heterogeneity between the studies included in our analysis 
besides our sub-analysis of mutagenicity index and rectal adenomas. In addition, in most cases, 
we did not observe indications for publication bias. However, we plotted funnel plots even in 
cases with less than ten studies and, thus, their power may be too low.  
Only three of the studies were cohort studies; most of the studies are of case-control design, 
which are prone to recall bias. 
Some studies [22, 27] found differences by adenoma size, which we could not examine 
because the number of studies was limited. For instance, Rohrmann et al. observed that PhIP 
intake was associated with a higher risk of small adenomas, but not large one [22]. On the 
contrary, Gunter et al. reported a positive association of BaP intake and risk of large (>1 cm), 
but not small adenomas [27]. 
Last, but not least, it is currently unclear if the association between HCA and BaP intake that 
has been observed in several studies is a causal association. Although the carcinogenicity of 
HCA and PAH has been proven in animal studies, it is disputable whether the intake in humans 
is sufficient to cause cancer. Rohrmann et al. have shown that the positive association 
between PhIP intake and CRA risk remained statistically significant, which was also true after 
mutually adjusting for other HCA [23]. On the other hand, Le et al. observed a positive 
association between PhIP intake from red meat and risk of proximal colon cancer but not PhIP 
from white meat [45]. This could indicate that the association between PhIP intake (or HCA 
intake in general) and cancer risk is not causal and that other mutagenic compounds, which 
arise from cooking of red meat, may be a risk factor for cancer. MDM, in contrast, integrates 




In conclusion, this meta-analysis suggests a potential association of HCAs, BaP, mutagenicity 
index with the risk of CRA, which is supported by dose-response relationships for PhIP, MeIQx 
and meat mutagenicity. Further studies are needed to analyse whether these associations 
have equal effects depending on sex, size and site of adenoma, which should be prospective in 
design to minimize biases common in case-control studies. In addition, the question whether 
HCA, PAHs or other yet unidentified components in red and processed meat are responsible 
for the observed associations need to be addressed.  
References 
1. American Cancer Society. Colorectal cancer facts & figures 2017-2019. 
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-
statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2017-
2019.pdf. Accessed 15 July 2017. 
2. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer 
incidence, mortality and prevalence worldwide in 2012. Lyon, France: IARC; 2013 Dec 
http://globocan.iarc.fr/. Accessed 15 July 2017. 
3. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with 
colorectal polyps. Practice Parameters Committee of the American College of 
Gastroenterology. Am J Gastroenterol. 2000;95: 3053-3063. 
4. Levine JS, Ahnen DJ. Adenomatous Polyps of the Colon. New England Journal of 
Medicine. 2006;355(24):2551-7. 
5. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, 
Forman D, Bray, F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on 
Cancer; 2014.  
6. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490-502. 
7. Willett WC. Diet and cancer: an evolving picture. JAMA. 2005; 293:233–234. 
8. Carr PR, Walter V, Brenner H, Hoffmeister M. Meat subtypes and their association with 
colorectal cancer: Systematic review and meta-analysis. Int. J. Cancer. 2016;138: 293–
302. doi:10.1002/ijc.29423. 
9. Bouvard V, Loomis D, Guyton KZ, Grosse Y, Ghissassi FE, Benbrahim-Tallaa L, et al. 
Carcinogenicity of consumption of red and processed meat. The Lancet 
Oncology.16(16):1599-600. 
10. Lippi G, Mattiuzzi C, Cervellin G. Meat consumption and cancer risk: A critical review of 
published meta-analyses. Critical Reviews in Oncology/Hematology. 2016;97:1-14. 
11. Domingo JL, Nadal M. Carcinogenicity of consumption of red meat and processed meat: 
A review of scientific news since the IARC decision. Food and Chemical Toxicology. 
2017;105:256-61. 
12. Abid Z, Cross AJ, Sinha R. Meat, dairy, and cancer. Am J Clin Nutr. 2014;100 Suppl 
1:386S-93S. 
13. IARC monographs on the evaluation of carcinogenic risks to humans. Ingested nitrate 
and nitrite, and cyanobacterial peptide toxins. IARC Monogr Eval Carcinog Risks Hum. 
2010;94:v-vii, 1-412. 
14. Felton JS, Knize MG, Dolbeare FA, Wu R. Mutagenic activity of heterocyclic amines in 
cooked foods. Environ Health Perspect. 1994;102 Suppl 6:201-4 
15. World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, 
Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: 
AICR, 2007 
16. Vainio H, Heseltine E, Wilbourn J. Report on an IARC working group meeting on some 
naturally occurring substances. Int. J. Cancer.1993; 53: 535–537. 
doi:10.1002/ijc.2910530402. 
17. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Chemical 
Agents and Related Occupations. (8)Lyon (FR): International Agency for Research on 
Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 
No. 100F.)  https://www.ncbi.nlm.nih.gov/books/NBK304416/. 
18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097. 
19. Wells G A, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell  P. The 
Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in 
Meta-Analyses. 2015. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.  
20. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-
response data. Am J Epidemiol. 1992; 135(11):1301-1309 
21. Egger M, Davey Smith G, Schneider M. Bias in meta-analysis detected by a simple, 
graphical test. BMJ. 1997; 315, 629–634. 
22. Wu K, Giovannucci E, Byrne C, Platz EA, Fuchs C, Willett WC, Sinha R. Meat mutagens 
and risk of distal colon adenoma in a cohort of U.S. men. Cancer Epidemiol. Biomark. 
Prev. 2006; 15, 1120–1125. 
23. Rohrmann S, Hermann S, Linseisen J. Heterocyclic aromatic amine intake increases 
colorectal adenoma risk: Findings from a prospective European cohort study. Am. J. 
Clin. Nutr. 2009; 89, 1418–1424. 
24. Ferrucci LM, Sinha R, Huang WY, Berndt SI, Katki HA, Schoen RE, Hayes RB, Cross AJ. 
Meat consumption and the risk of incident distal colon and rectal adenoma. Br. J. 
Cancer. 2012; 106, 608–616. 
25. Sinha R, Kulldorff, M Chow, WH, Denobile J, Rothman, N. Dietary intake of heterocyclic 
amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer 
Epidemiol. Biomark. Prev. 2001; 10,559–562. 
26. Sinha R, Kulldorff M, Gunter MJ, Strickland P, Rothman N. Dietary benzo[a]pyrene 
intake and risk of colorectal adenoma. Cancer Epidemiol. Biomark. Prev. 2005; 14, 
2030–2034. 
27.  Sinha R, Peters U, Cross AJ, Kulldorff M, Weissfeld JL, Pinsky PF, Rothman N, Hayes RB. 
Meat, meat cooking methods and preservation, and risk for colorectal adenoma. 
Cancer Res. 2005; 65, 8034–8041. 
28.  Gunter MJ, Probst-Hensch NM, Cortessis VK, Kulldorff M, Haile RW, Sinha R. Meat 
intake, cooking-related mutagens and risk of colorectal adenoma in a sigmoidoscopy-
based case-control study. Carcinogenesis 2005; 26, 637–642. 
29. Ferrucci LM, Sinha, R Graubard, BI, Mayne ST, Ma X, Schatzkin A, Schoenfeld PS, Cash 
BD, Flood A, Cross AJ. Dietary meat intake in relation to colorectal adenoma in 
asymptomatic women. Am. J. Gastroenterol. 2009; 104, 1231–1240. 
30.  Wang H, Yamamoto JF, Caberto C, Saltzman B, Decker R, Vogt TM, Yokochi L, Chanock 
S, Wilkens LR, Le Marchand L. Genetic variation in the bioactivation pathway for 
polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal 
neoplasia. Carcinogenesis. 2011; 32, 203–209. 
31. Fu Z, Shrubsole MJ, Smalley WE, Wu H, Chen Z, Shyr Y, Ness RM, Zheng W. Association 
of meat intake and meat-derived mutagen exposure with the risk of colorectal polyps 
by histologic type. Cancer Prev. Res. 2011; 4, 1686–1697. 
32.  Budhathoki S, Iwasaki M, Yamaji T, Sasazuki S, Takachi R, Sakamoto H, Yoshida T, 
Tsugane S. Dietary heterocyclic amine intake, NAT2 genetic polymorphism, and 
colorectal adenoma risk: The colorectal adenoma study in Tokyo. Cancer Epidemiol. 
Biomark. Prev. 2015; 24, 613–620. 
33.  Ho V, Peacock S, Massey TE, Ashbury JE, Vanner SJ, King WD. Meat-derived 
carcinogens, genetic susceptibility and colorectal adenoma risk. Genes Nutr. 2014; 9, 
430. 
34. Shin A, Shrubsole MJ, Ness RM, Wu H, Sinha R, Smalley WE, et al. Meat and meat-
mutagen intake, doneness preference and the risk of colorectal polyps: the Tennessee 
Colorectal Polyp Study. Int J Cancer. 2007;121(1):136-42. 
35. (9, 10)Shin A, Shrubsole MJ, Rice JM, Cai Q, Doll MA, Long J, et al. Meat intake, 
heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to 
colorectal polyp risk. Cancer Epidemiol Biomarkers Prev. 2008;17(2):320-9. 
36. (11, 12)Gilsing AM, Berndt SI, Ruder EH, Graubard BI, Ferrucci LM, Burdett L, et al. 
Meat-related mutagen exposure, xenobiotic metabolizing gene polymorphisms and the 
risk of advanced colorectal adenoma and cancer. Carcinogenesis. 2012;33(7):1332-9. 
37. Voutsinas J, Wilkens LR, Franke A, Vogt TM, Yokochi LA, Decker R, et al. Heterocyclic 
amine intake, smoking, cytochrome P450 1A2 and N-acetylation phenotypes, and risk 
of colorectal adenoma in a multiethnic population. Gut. 2013;62(3):416-22. 
38. Barbir A, Linseisen J, Hermann S, Kaaks R, Teucher B, Eichholzer M, et al. Effects of 
phenotypes in heterocyclic aromatic amine (HCA) metabolism-related genes on the 
association of HCA intake with the risk of colorectal adenomas. Cancer Causes Control. 
2012;23(9):1429-42. 
39. Fu Z, Shrubsole MJ, Li G, Smalley WE, Hein DW, Chen Z, et al. Using gene-environment 
interaction analyses to clarify the role of well-done meat and heterocyclic amine 
exposure in the etiology of colorectal polyps. Am J Clin Nutr. 2012;96(5):1119-28. 
40. Martinez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, et al. Meat intake, 
preparation methods, mutagens and colorectal adenoma recurrence. Carcinogenesis. 
2007;28(9):2019-27. 
41. Strum WB. Colorectal Adenomas. New England Journal of Medicine. 
2016;374(11):1065-75. 
42. Sinha R, Rothman N. Exposure assessment of heterocyclic amines (HCAs) in 
epidemiologic studies. Mutat Res. 1997;376(1-2):195-202. 
43. Stowers SJ, Anderson MW. Formation and persistence of benzo(a)pyrene metabolite-
DNA adducts. Environ Health Perspect. 1985;62:31-9 
44. Rothman N, Poirier MC, Baser ME, Hansen JA, Gentile C, Bowman ED, et al. Formation 
of polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells during 
consumption of charcoal-broiled beef. Carcinogenesis. 1990;11(7):1241-3. 
45. Le, NT, Michels FAS, Song M, Zhang X, Bernstein AM, Giovannucci EL et al. A 
prospective analysis of meat mutagens and colorectal cancer in the Nurses' Health 
Study and the Health Professionals Follow-up Study. Environ Health Perspect. 
2016;124:1529–36. 
46. Mignone LI, Giovannucci E, Newcomb PA, et al. Meat consumption, heterocyclic 
amines, NAT2 and the risk of breast cancer. Nutrition and cancer. 2009;61(1):36-46.  
47. Lee H-J, Wu K, Cox DG, et al. Polymorphisms in xenobiotic metabolizing genes, intakes 
of heterocyclic amines and red meat, and postmenopausal breast cancer. Nutrition and 
cancer. 2013;65(8):10.1080/01635581.2013.824991. 
48.  Fu Z, Deming SL, Fair AM, Shrubsole MJ, Wujcik DM, Shu XO, Kelley M, Zheng W. Well-
done meat intake and meat-derived mutagen exposures in relation to breast cancer 
risk: the Nashville Breast Health Study. Breast Cancer Res Treat. 2011;129:919–28. 
49. Lin J, Forman MR, Wang J, et al. Intake of red meat and heterocyclic amines, metabolic 
pathway genes and bladder cancer risk. International Journal of Cancer. 
2012;131(8):1892-1903. doi:10.1002/ijc.27437. 
50. Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and 
processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate 
cancer. Nutrition Journal. 2015;14:125. doi:10.1186/s12937-015-0111-3. 
51. Sander A, Linseisen J, Rohrmann S. Intake of heterocyclic aromatic amines and the risk 
of prostate cancer in the EPIC-Heidelberg cohort. Cancer Causes & Control. 
2011;22(1):109-14. 
52. Raskov H, Pommergaard HC, Burcharth J, Rosenberg J. Colorectal carcinogenesis-
update and perspectives. World Journal of Gastroenterology: WJG. 2014;20(48):18151-
18164.  
53. Platt KL, Edenharder R, Aderhold S, Muckel E, Glatt H. Fruits and vegetables protect 
against the genotoxicity of heterocyclic aromatic amines activated by human 
xenobiotic-metabolizing enzymes expressed in immortal mammalian cells. Mutation 
Research/Genetic Toxicology and Environmental Mutagenesis. 2010;703(2):90-8. 
54. Puangsombat K, Jirapakkul W, Smith JS. Inhibitory Activity of Asian Spices on 
Heterocyclic Amines Formation in Cooked Beef Patties. Journal of Food Science. 
2011;76(8):T174-T80. 
55. Zhang J, Empl MT, Schwab C, Fekry MI, Engels C, Schneider M, et al. Gut microbial 
transformation of the dietary imidazoquinoxaline mutagen MeIQx reduces its cytotoxic 
and mutagenic potency. Toxicol Sci. 2017. 
56. Chiavarini M, Bertarelli G, Minelli L, Fabiani R. Dietary Intake of Meat Cooking-Related 
Mutagens (HCAs) and Risk of Colorectal Adenoma and Cancer: A Systematic Review and 
Meta-Analysis. Nutrients. 2017;9(5). 
57. Iwasaki M, Mukai T, Takachi R, Ishihara J, Totsuka Y, Tsugane S. Validity of a self-
administered food frequency questionnaire in the estimation of heterocyclic aromatic 




Figure 1: Flow diagram of systematic literature search on meat mutagens and CRA risk. 
Describes the search strategy to examine the association between meat mutagens and the risk 
of colorectal adenomas (CRA) 
 
Figure 2: Meta-analyses of the associations between meat mutagens and CRA risk by study 
type. Shows forest plots of the association between intake of PhIP (A), MeIQx (B), 
DiMeIQx (C), BaP (D), and mutagenicity index (E) with CRA 
 
Figure 3: Non-linear dose-response analyses of meat mutagens and CRA risk. Shows dose-
response relationships between intake of PhIP (A), MeIQx (B), DiMeIQx (C), BaP (D), 
and mutagenicity index (E) with CRA 
 
Figure 4: Funnel plots of the analyses of meat mutagens and CRA risk. Shows funnel plots of 
the association between intake of PhIP (A), MeIQx (B), DiMeIQx (C), BaP (D), and 


























Wu et al, 
2006 
HPFS (US) Cohort 14,032 
(581) 
Men only 









Age, family history of colorectal cancer, 
reason for endoscopy, negative endoscopy 
before 1996, physical activity, smoking status, 
race, aspirin use, total energy intake, calcium 
and folate intake 
 
Rohrmann 
et al, 2009 




1994-1998 5.4 ± 2.4 
cases 








Energy intake without energy from alcohol, 
ethanol intake, milk and milk product 
consumption, fiber consumption, BMI, family 
history of colorectal cancer, physical activity, 
intake of nonsteroidal anti-inflammatory 
drugs, smoking, pack-years of smoking, 





PLCO (US) Cohort 17,072 
(1,008) 











Age at baseline, study centre, gender, 
ethnicity, education, family history of 
colorectal cancer, NSAIDS use, physical 
activity, smoking status, alcohol intake, 
dietary calcium, supplemental calcium, 
dietary fibre, total energy intake 
 





















Age, gender, total caloric intake, fiber intake, 
reason for screening, physical activity level, 
pack-years of cigarette smoking, use of 
NSAIDs, and white meat 
 













1994-1996  BP Colorectal 
adenoma 
Age, gender, total caloric intake, fiber intake, 
reason for screening, physical activity level, 
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Age, gender, screening center, energy intake, 
ethnicity, educational attaintment, tobacco 
use, alcohol use, use of aspirin and ibuprofen 
separately, vigorous physical activity, total 
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Adenoma Age, education, race, smoking status, physical 
activity, BMI, study center, current HRT use, 
family history of colorectal polyps or cancer, 
regular NSAID use, alcohol intake, fiber, 
dietary calcium, calcium from supplements, 
total caloric intake 
 
HPFS, Health Professionals Follow-up Study; EPIC European Prospective Investigation into Cancer and Nutrition; PLCO, Prostate, Lung, Colorectal, Ovarian Screening Trial; 
CONCeRN, Colorectal Neoplasia screening with Colonoscopy in asymptomatic women at Regional Navy/army medical centers; TCPS, Tennessee Colorectal Polyp Study; BMI, 
Body mass index; NSAIDs non-steroidal anti-inflammatory drugs; HPP, hyperplastic polyp 
Wang et al, 
2010 






























Age, sex, ethnicity, daily energy intake, 
lifetime hours of recreational physical activity 
and additionally for recruitment site and 
examination procedure, BMI, pack-years of 
smoking, alcohol intake, folate intake in the 
adenoma study and BMI 5 years before 
diagnosis, ever use of aspirin, years of 
schooling, daily intake of calcium 
 
 












Adenomas, HPP Age, sex, race, study sites, educational 
attainment, indications for colonoscopy, 
smoking, alcohol consumption, BMI, physical 
activity, regular NSAIDs use, total energy 
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colonoscopy 
 













Sex, smoking status, fruit and vegetable 
intake, dietary fiber intake and biomarker 
levels of albumin and folate 
 
Budhathoki 





















Age, screening period, smoking, alcohol 
consumption, body mass index, physical 
activity, family history of colorectal cancer, 
and NSAID use. Further adjusted in females: 
age at menarche, menopausal status, and 
current use of hormones 
Table 2. Associations between meat mutagens and CRA by sex and site 
Mutagen Number of studies Results 
[OR (95% CI)] 
Test of 
heterogeneity p 
PhIP    
male 3 1.11 (0.89, 1.38) 0.453 
female 3 1.18 (0.71, 1.96) 0.157 
colon 4 1.18 (1.04, 1.33) 0.317 
rectum 3 1.23 (0.86, 1.76) 0.086 
    
MelQx    
male 3 1.20 (0.95, 1.51) 0.510 
female 3 1.58 (1.09, 2.30) 0.498 
colon 3 1.14 (0.99, 1.31) 0.293 
rectum 2 0.90 (0.65, 1.26) 0.174 
    
DiMelQx    
male 2 1.09 (0.87, 1.36) 0.827 
female 2 1.09 (0.67, 1.77) 0.731 
colon 3 1.04 (0.91, 1.19) 0.229 
rectum 2 0.99 (0.74, 1.34) 0.177 
    
B(a)P    
male    
female    
colon 2 1.06 (0.83, 1.35) 0.062 
rectum 2 1.27 (0.94, 1.72) 0.168 
    
Mutagenicity index    
male 2 1.46 (0.87, 2.47) 0.241 
female 2 1.13 (0.43, 2.92) 0.096 
colon 3 1.12 (0.97, 1.29) 0.261 





Records identified through database searching 
n = 334 from PubMed 


































Records after duplicates removed 
n = 465 
Records excluded based on 
title/abstract 
n = 437 
Full-text articles assessed for eligibility 
n = 31 
Full-text articles excluded 
n = 19 
 
- Examine genetics only (n=5) 
- overlap with other (n=9) 
- adenoma recurrence (n=1) 
- other (n=4) 
Studies included in 
qualitative synthesis 
 12 publications 
3 cohort, 8 case-control, 1 
cross-sectional 
 
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.459)
Ho et al, 2014
Ferruci et al, 2009
Ferruci et al, 2012
Case-control
Fu et al, 2011
Subtotal  (I-squared = 3.0%, p = 0.410)
Sinha et al, 2005, PLCO
Rohrmann et al, 2009
Wu et al, 2006
ID
Subtotal  (I-squared = 17.1%, p = 0.299)
Sinha et al, 2001
Gunter et al, 2005
Wang et al, 2010
Study
Budhathoki et al, 2015 (women)
Cohort




































NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 32.5%, p = 0.131)
Rohrmann et al, 2009
Cohort
Ferruci et al, 2012
Wu et al, 2006
Ferruci et al, 2009
Budhathoki et al, 2015 (men)
Ho et al, 2014
Sinha et al, 2001
Wang et al, 2010
Budhathoki et al, 2015 (women)
Subtotal  (I-squared = 38.6%, p = 0.111)
Fu et al, 2011
Case-control
Sinha et al, 2005, PLCO
Subtotal  (I-squared = 29.5%, p = 0.242)






































NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 30.2%, p = 0.167)
Wu et al, 2006
ID
Fu et al, 2011
Ferruci et al, 2009
Sinha et al, 2001
Wang et al, 2010
Ho et al, 2014
Subtotal  (I-squared = 0.0%, p = 0.548)
Gunter et al, 2005
Ferruci et al, 2012
Case-control
Subtotal  (I-squared = 42.2%, p = 0.109)
Rohrmann et al, 2009


































NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 47.5%, p = 0.076)
Ferruci et al, 2009
Ho et al, 2014
Fu et al, 2011
Ferruci et al, 2012




Wu et al, 2006
Subtotal  (I-squared = 60.5%, p = 0.038)
Sinha et al, 2005



























NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 10.6%, p = 0.348)
Ferrucci et al, 2012
Subtotal  (I-squared = 15.8%, p = 0.314)
Sinha et al, 2005, PLCO
Sinha et al, 2005
Case-control
Ferrucci et al, 2009
Gunter et al, 2005
ID
Fu et al, 2011
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E. Mutagenicity Index 
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p (EggerTest) = 0.014
E. Mutagenicity Index
0.01 < p < 0.05
0.05 < p < 0.10
p > 0.10
